Company Introduction

MedKey Clinical has been deeply engaged in the clinical research field for over a decade. We have facilitated successful approval pathways and commercial rollouts for a wealth of innovative assets, with over 370 projects successfully approved for marketing to date: first-in-class and China-first breakthroughs covering medical devices and pharmaceuticals across all key therapeutic fields. We are committed to continuously bringing innovative treatment options to patients and accelerating their access to new drugs.
Representative Recent Approvals:

1. Enoglutide Injection | Approved in January 2026 | The world's first approved cAMP-biased GLP-1 receptor agonist

2. Multifocal Intraocular Lens | Approved in August 2025 | China's first innovative trifocal intraocular lens

3. Mazdutide Injection | Approved in June 2025 | The world's first approved GCG/GLP-1 dual receptor agonist for weight loss

4. Meloxicam Injection (III) | Approved in June 2025 | China's first approved intravenous sodium crystal product

5. Angoseriximab Injection | Approved in May 2025 | The first domestic PCSK9-targeted drug approved for statin-intolerant populations

6. Risankizumab Injection | Approved in March 2025 | The world's first IL-23 inhibitor approved for adult patients with moderately to severely active Crohn's disease, and the first IL-23 inhibitor in China with a handheld auto-injector

7. Transcatheter Tricuspid Valve Device | Approved in March 2025 | China's first transcatheter tricuspid valve device

8. Stedustamab Injection | Approved in February 2025 | A first-in-class recombinant monoclonal antibody against tetanus toxin

9. Spgiribamab for Injection | Approved in February 2025 | The world's first IL-4Ra biologic for seasonal allergic rhinitis

10. Ciltacabtagene Autoleucel Injection | Approved in July 2023 | The world's first fully human BCMA-targeted CAR-T therapy, and China's first indigenously developed, fully process-manufactured cell therapy product